Lewis, John A. (1995) Statistical issues in the regulation of medicines. Statistics in Medicine, 14 (2). pp. 127-136. ISSN 0277-6715. (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided)
The recent release within the European Union of a draft Note for Guidance from the Commission for Proprietary Medical Products (CPMP) entitled 'Biostatistical methodology in clinical trials in applications for marketing authorisations for medicinal products' has stimulated widespread discussion of the relevant statistical issues. This discussion contains echoes of an earlier debate concerning a closely related U.S. Guideline. The areas of agreement and disagreement between the two guidelines bear close examination as they provide lessons for all statisticians involved in the design and analysis of clinical trials. Notable areas of debate include crossover designs, multi-centre trials, the intention to treat principle, pre-specification of statistical analysis and the ability to generalize results to the wider population of patients. The consequences for the routine involvement of statisticians in this area of work in general, and in the regulatory process in particular, are especially important. This is an illustration of the extent to which drug regulation has influenced, and is continuing to influence, the development of medical statistics throughout the world.
|Subjects:||Q Science > QA Mathematics (inc Computing science)
|Divisions:||Faculties > Science Technology and Medical Studies > School of Mathematics Statistics and Actuarial Science|
|Depositing User:||O.O. Odanye|
|Date Deposited:||07 Jun 2009 20:41|
|Last Modified:||06 May 2014 14:31|
|Resource URI:||https://kar.kent.ac.uk/id/eprint/19348 (The current URI for this page, for reference purposes)|